PHILADELPHIA, PA — Medicus Pharma (NASDAQ: MDCX) has reworked the economics of its lead urology and oncology program, cutting royalty obligations tied to Teverelix in half while preserving full global rights and intellectual property control.
The company said its subsidiary, Antev Ltd., entered into a third amendment to its license agreement with LifeArc, reducing the royalty rate on worldwide net sales of Teverelix from roughly 4% to 2%. The amendment also clarifies the royalty term on a country-by-country basis, aligning the agreement with standard pharmaceutical industry practice.
Medicus said the revised terms materially improve the long-term economics of Teverelix without altering development responsibilities, license scope, or ownership of underlying intellectual property. All other provisions of the original agreement remain in effect.
Dr. Raza Bokhari, Medicus’ executive chairman and chief executive officer, said the streamlined royalty structure enhances the program’s appeal to potential partners as the company advances Teverelix toward later-stage development and commercialization.
Teverelix is being developed as a first-in-class therapy for acute urinary retention relapse prevention and as a best-in-class option for prostate cancer patients with elevated cardiovascular risk. Medicus estimates the combined market opportunity for those indications at approximately $6 billion.
The license grants Medicus exclusive, worldwide rights to develop, manufacture, and commercialize Teverelix, including the ability to sublicense across multiple tiers. The company retains full operational control over development and commercialization, while owning all program-specific improvements generated by its teams and affiliates. Teverelix is supported by a global patent portfolio covering major pharmaceutical markets.
Medicus said the amended agreement reflects scientific progress made by the Antev team, including additional supporting data and continued expansion of the Teverelix intellectual property estate, while simplifying the economic framework to support long-term execution.
Teverelix is a long-acting injectable GnRH antagonist formulated as a microcrystalline suspension. Unlike GnRH agonists, which trigger an initial hormonal surge, Teverelix provides immediate receptor antagonism, rapidly suppressing LH, FSH, and downstream sex hormones without flare. The mechanism may hold particular relevance for advanced prostate cancer patients with cardiovascular risk, though the company noted that further clinical validation is required.
Beyond Teverelix, Medicus continues to advance SkinJect, its dissolvable microneedle platform for the non-invasive delivery of doxorubicin in basal cell carcinoma. The company said Phase 2 enrollment has been completed across nine U.S. sites, with topline data expected in the first quarter of 2026 and an end-of-Phase 2 FDA meeting planned for the first half of the year.
Medicus said its broader strategy remains focused on advancing programs through Phase 2 proof-of-concept before pursuing licensing or strategic partnerships with established pharmaceutical companies for late-stage development and commercialization.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.